Analystreport

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $6.70 price target on the stock.

Cidara Therapeutics, Inc.  (CDTX) 
Last cidara therapeutics, inc. earnings: 3/4 05:55 am Check Earnings Report
US:NASDAQ Investor Relations: ir.cidara.com